Abstract
There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Current Molecular Medicine
Title: Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB
Volume: 7 Issue: 3
Author(s): Kerstin J. Williams and Ken Duncan
Affiliation:
Keywords: Tuberculosis, drug discovery, essential gene, target validation
Abstract: There is an urgent need for new drugs to treat tuberculosis. During the last forty years the only drugs to have been developed are variations on existing ones, but new drug candidates must offer improvements over existing agents. In particular, we require new drugs having novel mechanisms of action that are active against drug-resistant strains and also kill persistent bacilli, thus shortening the length of chemotherapy. Recent advances in our understanding of the biology of Mycobacterium tuberculosis, in particularly the availability of the genome sequence coupled with development of new genetic tools, have greatly contributed to the discovery of potential drug targets for new antituberculars. However, although many potential new drug targets have been identified, greater effort is required in target validation to show properly that they are essential for bacterial growth and survival. In this review, the current drug development pipeline and the strategies employed to identify and validate novel tuberculosis drug targets are presented.
Export Options
About this article
Cite this article as:
Williams J. Kerstin and Duncan Ken, Current Strategies for Identifying and Validating Targets for New Treatment-Shortening Drugs for TB, Current Molecular Medicine 2007; 7 (3) . https://dx.doi.org/10.2174/156652407780598575
DOI https://dx.doi.org/10.2174/156652407780598575 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Antidepressant Treatment of Social Anxiety Disorder: A Review
Current Clinical Pharmacology Current Studies of Osteoclastogenesis and Potential Drug Targets
Current Drug Targets Biologicals Dramatic Advances in the Treatment of Psoriasis
Current Pharmaceutical Design Human Tuberculosis I. Epidemiology, Diagnosis and Pathogenetic Mechanisms
Current Medicinal Chemistry Prospects for Developing New Antibacterials Targeting Bacterial Type IIA Topoisomerases
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
Combinatorial Chemistry & High Throughput Screening Recent Trends on the Development of Machine Learning Approaches for the Prediction of Lysine Acetylation Sites
Current Medicinal Chemistry A Comparative Study to Explore the Effect of Different Compounds in Immune Proteins of Human Beings Against Tuberculosis: An In-silico Approach
Current Bioinformatics Adjunctive Immunotherapy of Mycobacterial Infections
Current Pharmaceutical Design Importance of a Potential Salt Bridge and Hydrophobic Core in the Function and Oligomerization of a Small Heat Shock Protein
Protein & Peptide Letters Modulation of Neutrophil Development and Homeostasis
Current Molecular Medicine From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
Current Pharmaceutical Biotechnology Editorial: [A Threat to One is a Threat to All – Biosecurity for the Western World Starts in Developing Countries: Do We Speak the Same Language of Hygiene?]
Inflammation & Allergy - Drug Targets (Discontinued) Structural Characterization of Alpha-methylacyl-CoA Racemase: Comparative Structural Modeling, Molecular Docking and Dynamic Simulations Studies
Current Cancer Drug Targets Structure and Function of RNase AS: A Novel Virulence Factor From Mycobacterium tuberculosis
Current Medicinal Chemistry Green Formation of Novel Pyridinyltriazole-Salicylidene Schiff Bases
Current Organic Synthesis Pathogen Interactions with DC-SIGN Modulate Immune Responses: A Toll Tale?
Current Immunology Reviews (Discontinued) Bacterial β-ketoacyl-Acyl Carrier Protein Synthases as Targets for Antibacterial Agents
Current Protein & Peptide Science Anti-Tuberculosis
Current Bioactive Compounds